Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to -$71000.0.

  • Barinthus Biotherapeutics' Tax Provisions fell 226666.67% to -$71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$115000.0, marking a year-over-year increase of 8673.59%. This contributed to the annual value of -$44000.0 for FY2024, which is 9856.91% up from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Tax Provisions is -$71000.0, which was down 226666.67% from -$25000.0 recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Tax Provisions high stood at $151000.0 for Q4 2021, and its period low was -$2.0 million during Q4 2022.
  • Over the past 5 years, Barinthus Biotherapeutics' median Tax Provisions value was -$65000.0 (recorded in 2021), while the average stood at -$400894.7.
  • In the last 5 years, Barinthus Biotherapeutics' Tax Provisions crashed by 952857.14% in 2022 and then skyrocketed by 10036.59% in 2024.
  • Over the past 5 years, Barinthus Biotherapeutics' Tax Provisions (Quarter) stood at $151000.0 in 2021, then plummeted by 1437.09% to -$2.0 million in 2022, then soared by 59.39% to -$820000.0 in 2023, then surged by 100.37% to $3000.0 in 2024, then tumbled by 2466.67% to -$71000.0 in 2025.
  • Its Tax Provisions stands at -$71000.0 for Q3 2025, versus -$25000.0 for Q2 2025 and -$22000.0 for Q1 2025.